|
Professor JIA Yingjie’s clinical experience in treating cancerous fever in lung cancer |
Hits 631 Download times 349 Received:February 10, 2022 |
View Full Text View/Add Comment Download reader |
DOI
10.11656/j.issn.1672-1519.2022.05.05 |
Key Words
cancerous fever;lung cancer;clearing heat and nourishing yin;middle Jiao;JIA Yingjie |
Author Name | Affiliation | E-mail | ZHANG Chang | First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300381, China National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin 300381, China Graduate School, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China | | MOU Ruiyu | First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300381, China National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin 300381, China Graduate School, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China | | LI Xiaojiang | First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300381, China National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin 300381, China | zxqlovelxj@126.com |
|
Abstract
|
Professor JIA Yingjie believed that in the end stage of lung cancer,due to the deficiency of righteousness,the internal heat toxin leads to the consumption of yin fluid,which is often complicated by cancerous fever in the clinical diagnosis and treatment of cancerous fever in lung cancer by. It is concluded that the pathogenesis of cancerous fever of lung cancer is caused by the treatment of righteousness and heat toxin from the middle Jiao and the treatment of clearing heat and nourishing yin is summarized as the treatment method. The treatment also focuses on the care of the spleen and stomach,and pays attention to the patient's stool condition with remarkable clinical results. This article introduces in detail Professor JIA Yingjie's ideas on the treatment of cancerous fever in lung cancer for the benefit of fellow patients. |
|
|
|
|
|
|